Air Industries Group (AIRI) - 10-K Filing Summary
Business Context and Reporting Period
Company: Air Industries Group (AIRI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A leading manufacturer of precision components and assemblies for aerospace and defense prime contractors. The company operates as a Tier One and Tier Two supplier, producing landing gears, flight controls, and engine components primarily for the U.S. Government, international governments, and commercial airlines. Operations are conducted through two manufacturing centers in New York and Connecticut.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $55.1 million | $51.5 million |
| Gross Profit | $8.9 million | $7.4 million |
| Gross Margin | 16.2% | 14.4% |
| Operating Income (Loss) | $0.5 million | $(0.3) million |
| Net Loss | $(1.4) million | $(2.1) million |
| Cash from Operations | $0.3 million | $4.9 million |
| Total Debt (Current + Long Term) | $26.3 million | $23.3 million |
| Working Capital | $11.8 million | $12.1 million |
| Backlog (Funded) | $117.9 million | $98.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.0% to $55.1 million, driven by higher shipment volumes against an expanding backlog and a shift in customer mix.
- Margin Expansion: Gross margin improved to 16.2% from 14.4% due to sales volume increases, product mix shifts, and operating efficiencies.
- Profitability: The company returned to operating profitability ($0.5 million) compared to an operating loss in 2023, though a net loss of $1.4 million persisted due to interest expenses.
- Backlog Strength: Funded backlog grew 19.9% to $117.9 million. Total unfilled contract value (including potential LTA orders) stands at $271.3 million.
- Customer Concentration: Four customers accounted for 73.4% of net sales in 2024 (up from 64.2% in 2023). Northrop Grumman sales increased significantly (18.3% of sales vs. 3.6% in 2023), while Boeing sales declined (0.7% vs. 12.2%).
- Cash Flow: Operating cash flow decreased significantly to $0.3 million from $4.9 million, primarily due to the utilization of $2.4 million in customer deposits for raw material procurement.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management expects to boost sales in 2025 and attain profitability, supported by the $117.9 million funded backlog and potential orders under Long-Term Agreements (LTAs). The company plans to invest approximately $1.6 million in new equipment in 2025.
Going Concern Warning: The auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. This is due to the expiration of the Current Credit Facility on December 30, 2025, and the requirement to refinance approximately $18.1 million of debt. The company is actively seeking refinancing and has initiated an At-The-Market (ATM) equity offering to repay related party notes.
Key Risks:
- Debt Refinancing: Failure to refinance the $18.1 million Webster Bank facility or the $6.2 million related party notes (maturing July 2026) could lead to insolvency.
- Covenant Compliance: The company must meet specific EBITDA and Fixed Charge Coverage Ratio covenants. While compliant as of December 31, 2024, future compliance is not guaranteed.
- Customer Concentration: High reliance on a few prime contractors (RTX, Lockheed Martin, Northrop) creates vulnerability to contract cancellations or budget cuts.
- Internal Controls: A material weakness in internal controls over financial reporting regarding IT system data validation and segregation of duties remains unremediated as of December 31, 2024.
Legal Contingencies: An ongoing lawsuit with Contract Pharmacal Corp. regarding a sublease dispute (claim reduced to $700,000) is pending appeal. Management believes it has a meritorious defense.
Investor Verification Checklist
- Debt Refinancing Status: Verify progress on refinancing the $18.1 million Webster Bank facility maturing in December 2025 and the $6.2 million related party notes.
- Equity Offering Proceeds: Confirm the utilization of proceeds from the ATM offering (sold 326,791 shares for $1.4 million gross proceeds as of March 31, 2025) specifically for debt reduction.
- Covenant Compliance: Monitor quarterly reports for compliance with the Fixed Charge Coverage Ratio (1.05x required for Q1/Q2 2025) and EBITDA thresholds.
- Internal Control Remediation: Review updates on the remediation of the material weakness in IT financial reporting controls.
- Customer Mix Stability: Assess the sustainability of the increased sales to Northrop Grumman and the reduction in Boeing sales.